Cost-Effectiveness of an Intervention to Reduce HIV/STI Incidence and Promote Condom Use among Female Sex Workers in the Mexico–US Border Region by Burgos, José L. et al.
Cost-Effectiveness of an Intervention to Reduce HIV/STI
Incidence and Promote Condom Use among Female Sex
Workers in the Mexico–US Border Region
Jose ´ L. Burgos
1,2, Julia A. Gaebler
1, Steffanie A. Strathdee
1, Remedios Lozada
3, Hugo Staines
4, Thomas L.
Patterson
5*
1Division of Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, United States of America, 2Faculty of Medicine,
University of Xochicalco, Tijuana, Mexico, 3State Public Health Service, Tijuana, Mexico, 4Faculty of Medicine, Autonomous University of Ciudad Juarez, Ciudad Juarez,
Mexico, 5Department of Psychiatry, University of California San Diego, La Jolla, California, United States of America
Abstract
Background: Previous research demonstrated efficacy of a brief behavioral intervention to reduce incidence of HIV and
sexually transmitted infections (STIs) among female sex workers (FSWs) in Tijuana and Ciudad Juarez, Mexico, cities on
Mexico’s border with the US. We assessed this intervention’s cost-effectiveness.
Methodology and Principal Findings: A life-time Markov model was developed to estimate HIV cases prevented, changes
in quality-adjusted life expectancy (QALE), and costs per additional quality-adjusted life year gained (QALY), comparing (in
US$2,009) no intervention to a once-only and annual intervention. Future costs and health benefits were discounted
annually at 3%. Sensitivity analyses evaluated model robustness. We found that for a hypothetical 1,000 FSWs receiving the
once-only intervention, there were 33 HIV cases prevented and 5.7 months of QALE gained compared to no intervention.
The additional cost per QALY gained was US$183. For FSWs receiving the intervention annually, there were 29 additional
HIV cases prevented and 4.5 additional months of QALE compared to the once-only intervention. The additional cost per
QALY was US$1,075. When highly active antiretroviral therapy (HAART) was included in the model, the annual intervention
strategy resulted in net savings and dominated both once-only and no intervention strategies, and remained robust across
extensive sensitivity analyses. Even when considering clinical benefits from HAART, ignoring added costs, the cost per QALY
gained remained below three times the Mexican GDP per capita, and below established cost-effectiveness thresholds.
Conclusions/Significance: This brief intervention was shown to be cost-effective among FSWs in two Mexico-US border
cities and may have application for FSWs in other resource-limited settings.
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Introduction
The financial burden of the worldwide HIV epidemic surpasses
US$10 billion annually [1], and over US$270 million annually in
Mexico [2], where 88% of costs are attributable to highly active
antiretroviral therapy (HAART) [3]. In Mexico, HIV was until
recently thought to affect almost exclusively men reporting sex with
other men (MSM) [4]. However, the proportion of female AIDS
cases has increased steadily from 3% in 1986 [5] to more than 27%
in 2008, affecting approximately 57,000 Mexican women [6].
Baseline testing of FSWs in an intervention study in Tijuana and
Ciudad Juarez in 2006 found a strikingly high prevalence of HIV
infection compared to earlier studies of FSWs in Mexico. A 1997
study in Mexico City estimated HIV prevalence among FSWs
there at 0.6% [7]; by contrast, HIV prevalence among a large
sample of FSWs in Tijuana and Ciudad Juarez in 2006 was 6%,
and the same sample showed prevalence of any STI to be 25% [8].
Programs aimed at reducing HIV and STIs among FSWs are
thought to be cost-effective since they reduceHIV transmission from
high-riskgroupstothe general population inareaswithconcentrated
epidemics [9], [10]. In Tijuana and Ciudad Juarez, where com-
mercial sex work is quasi-legal and the sex trade is thriving [11], an
effective response to the HIV epidemic would include efficacious
interventions that have shown reductions in HIV inci-
dence among FSWs in community trials [12]. Considering Mexico’s
limited resources, which are even further constrained in the current
global financial crisis, effective public health interventions need to
prove their relative cost-effectiveness before being widely adopted.
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11413Mujer Segura (Healthy Woman) is a brief (35-minute) behavioral
intervention developed to increase condom negotiation skills and
reduce incidence of HIV and STIs among FSWs [11]. Between
2004 and 2006, 709 FSWs in Tijuana and Ciudad Juarez were
randomized to receive either Mujer Segura, which integrates
motivational interviewing and theoretical principles of behavior
change, or a time-equivalent didactic presentation critical to HIV
and STI prevention [13]. Among FSWs assigned to the
intervention, there was a statistically significant increase compared
to the control group in reported protected sex acts with clients
after six months of follow-up and a 40% reduction in STI
incidence (HIV, syphilis, gonorrhea, Chlamydia, or any combi-
nation of these). Of note, HIV incidence was zero per 100 person-
years in the intervention group versus 2.01 per 100 person-years
among FSWs assigned to the control group, as reported previously
[13]. We assessed cost-effectiveness of this intervention in reducing
HIV/STI incidence among FSWs in the northern Mexican border
region, to determine its potential for adoption as a preventive
health practice in other resource-limited settings.
Methods
Ethics Statement
The intervention study on which these analyses are based was
reviewed and approved by the Human Research Protections
Program of the University of California, San Diego (Project
#051182). The study was registered with ClinicalTrials.gov as
Protocol NCT00338845. Written consent was given by the
patients for their information received, stored, and used for this
research. The protocol for this trial and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocol S1. Please note that the page numbers in the
Checklist refer to the print version of an article that contains a full
description of the methods and results of the trial [13]. The same
article is available in full text or PDF from PubMed Central
(PMC2633868). The CONSORT Flow Chart for the protocol
may be seen in Figure 1.
Summary
We developed a state-transition Markov model using Treeage
Pro Suite software (Treeage Inc., 2009 release 1.0.2, Williams-
town, MA, USA) to evaluate cost-effectiveness of the Mujer Segura
intervention. A Monte Carlo simulation was conducted to
calculate clinical benefits (incident HIV infections and quality-
adjusted life years or QALYs) and lifetime costs comparing no
intervention to the Mujer Segura intervention offered once only or
annually. Strategies were compared by calculating the incremental
cost-effectiveness ratios (ICER), defined as the additional health
benefit of an intervention compared with the next least costly
strategy [14]. We adopted a government health care payer
perspective, the most relevant for health policy decision-making in
low- and middle-income countries. Costs are presented in
Figure 1. CONSORT flow chart. * All participants who completed follow-up were analyzed for STI incidence. Some participants were lacking
follow-up sexual risk data. See Table 2, p. 2054, in Patterson et al. (2008), Am J Public Health 98: 2051–2057 for details.
doi:10.1371/journal.pone.0011413.g001
Cost-Effective Intervention
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e11413US$2009 according to the 2009 consumer price index and
currency exchange rates published by the National Bank of
Mexico. Future costs and health benefits were discounted at an
annual rate of 3% as recommended by the U.S. Panel on Cost
Effectiveness in Health and Medicine [15]. Following the World
Health Organization recommendation, we considered an inter-
vention ‘‘highly cost-effective’’ if it was less than one time the per
capita gross domestic product (GDP) in Mexico per QALY gained
(equivalent to US$ 9,766) and ‘‘not cost-effective’’ if it was greater
than three times the per capita GDP per QALY gained (equivalent
to US$29,300) [16]. Study protocols were approved by the
responsible institutional review boards in the U.S. and Mexico.
Model structure
Risks of HIV and STI acquisition among FSWs were modeled
as a sequence of annual transitions between seven mutually
exclusive health states. As shown in Figure 2, FSWs enter the
model in one of three mutually exclusive health states free of HIV
infection: 1) No HIV or STIs; 2) non-ulcerative STI (i.e.,
gonorrhea or Chlamydia trachomatis); and 3) syphilis infection. After
entering the model, FSWs can remain in one of the initial states, or
transition to one of four additional states: 4) HIV infection with no
concurrent STIs; 5) HIV and a non-ulcerative STI; 6) HIV and
syphilis co-infection; and 7) death.
To track HIV progression within the Markov model, we created
a variable for CD4+ counts that modified health related quality of
life (HRQoL) values, costs, and AIDS-related mortality (Table 1).
For example, we assumed that in a person who acquired HIV
infection, CD4+ cell counts would decline by 25% during the first
year and by 60 cells annually thereafter [17]. For FSWs receiving
HAART, we assumed that CD4+ cell counts would increase by
100 cells for the first year on HAART and by 60 cells annually
thereafter, until the CD4+ cell count reached 500 [18].
Monte Carlo simulation
We conducted a Monte Carlo simulation in which individual
women with unique characteristics were tracked and followed over
their lifetimes [14]. Individual characteristics (initial age, injection
drug use, baseline CD4 counts, and years remaining in sex work)
of each FSW were randomly assigned using distributions derived
from the Mujer Segura cohort and other studies [8], [13], [17], [19].
We first conducted the simulation assuming no access to HAART,
and subsequently assuming universal access to HAART, initiated
according to CD4+ cell count thresholds using data from
published reports from Mexico [3], [19]. We reported the number
of HIV infections averted and quality-adjusted life expectancy
(QALE) comparing no intervention with the Mujer Segura
intervention offered once only, and the Mujer Segura intervention
offered annually for a cohort of 1,000 FSWs. Based on previous
studies [20], we assumed that FSWs retire from sex work after the
age of 57 and stop receiving the Mujer Segura behavioral
intervention. Additionally, after leaving sex work, the risk for
HIV infection and STIs is adjusted according to the age of the
general female population in the U.S.-Mexican border region
[21].
Model parameters
Base case clinical and epidemiological variables used to
characterize the population of FSWs are presented in Table 2.
Variables include the prevalence and incidence of STIs among
FSWs [13], annual risk for HIV infection, annual background
mortality according to age for Mexican women [22], increased
mortality from HIV infection according to CD4 cell counts in the
absence of HAART [17], response to HAART [18], years in sex
work [20], HAART initiation according to CD4 cell counts
thresholds [3], [19], and efficacy of the Mujer Segura intervention
for reducing HIV/STI incidence among FSWs [13], [23], [24].
Base case costs used in the model are summarized in Table 3.
Costs were obtained using an ingredients approach [14] for the
observed costs per screening (e.g., STI screening, personnel time
costs during counseling) during the Mujer Segura study. For fixed
costs such as space rental and administrative personnel expendi-
tures, we used a step-down approach [14]. Costs associated with
treatment of STIs and HIV infections were obtained from the
National Center for AIDS Prevention in Mexico (CENSIDA) and
published reports from Mexico [3], [25].
Figure 2. Schematic representation of the Markov model used for the cost effectiveness analysis for the Mujer Segura intervention.
a=Female sex workers; b=No HIV or sexually transmitted infections; c=Gonorrhea or Chlamydia trachomatis infection; d=Syphilis infection; e=HIV
infection (no other sexually transmitted infections); f=HIV and gonorrhea or Chlamydia co-infection; g=HIV and syphilis co-infection.
doi:10.1371/journal.pone.0011413.g002
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To account for parameter uncertainty, we conducted one-, two-,
and multi-way sensitivity analyses for all input values according to
95% confidence intervals (CI) derived from the Mujer Segura cohort
study and for the likely range of other inputs according to an
extensive literature review, to encompass plausible low and high
values (Tables 2–3). We performed a second-order Monte Carlo
simulation for a multivariate probabilistic sensitivity analysis using
probability distributions from the Mujer Segura study and published
reports [3], [17], [18], [19], [26]. These methods involved 500
parallel simulations of 10,000 individual random walks each, using
different probability distributions to calculate robust confidence
intervals. To generate a cost-effectiveness acceptability curve, we
conducted a probabilistic sensitivity analysis using Monte Carlo
simulation methods modifying the effectiveness of the intervention
to reduce HIV incidence using a triangular probability distribution
[27] with a range between 0% and 60% with 40% effectiveness as
best estimate. Finally, we used multi-way sensitivity analyses to
explore combined effects to represent the general female population
of Tijuana and Ciudad Juarez.
Model calibration
We calibrated our model by comparing estimates of life
expectancy, HIV incidence, and median survival for women not
in sex work to estimates from the 2009 U.S.–Mexico Border
Epidemiological Profile [21], the 2005 Centers for Disease Control
and Prevention (CDC) HIV/AIDS surveillance report [28], and
demographic data from the National Mexican Population Council
(CONAPO) [22]. None of these data sources were used to develop
the model.
Role of the funding source
The sponsor of the Mujer Segura behavioral intervention study
(National Institute of Mental Health) had no role in designing the
study, in the collection, analysis, or interpretation of the data, in
Table 1. CD4+ counts and changes in mortality and health-
related quality of life values used for the base case analysis.
CD4+ cells
a IRR
b QALY
c
.450 1 0.98
400–450 1.41 0.96
300–399 1.45 0.94
200–299 1.66 0.94
100–199 2.59 0.87
50–99 4.63 0.81
0–49 11.63 0.79
aNumber of CD4+ cells per micro liter.
bIncidence rate ratio.
cQuality-adjusted life years.
doi:10.1371/journal.pone.0011413.t001
Table 2. Model base case clinical values and ranges used for sensitivity analyses.
Variable Base Case (range) Source
Clinical values Baseline CD4+ counts
a 750 (600–1200) [1], [17]
Annual CD4+ count decline
a 60 (37–77) [17]
Annual CD4 count increase
a 100 (60–120) [18]
Epidemiological values Syphilis incidence
b 7.75 (3.6–11) [13]
Gonorrhea incidence
b 8 (3.8–12.19) [13]
Chlamydia incidence
b 10.5 (5.51–15) [13]
HIV incidence
b 2.01 (1–3) [13]
Mujer Segura effectiveness
c 40% (20–60%) [13], [23], [24]
Probability of leaving sex work
b 21.5 (10–35) [20]
Background mortality Life tables [22]
HIV/AIDS medical costs (annual) CD4+ cell counts:
More than 350 $3,745
d [3], [25]
Between 200–349 $4,186
d [3], [25]
Between 100–199 $4,287
d [3], [25]
Less than 100 $5,305
d [3], [25]
Annual probability of initiating HAART
e CD4+ cell counts:
More than 350 9%
d [3], [19]
Between 200–349 40%
d [3], [19]
Between 100–199 49%
d [3], [19]
Less than 100 6%
d [3], [19]
acells per microliter.
bPer 100 person years.
cRisk reduction for sexually transmitted infections among female sex workers.
dProbability distribution used for probabilistic sensitivity analysis.
eHighly Active Antiretroviral Therapy.
doi:10.1371/journal.pone.0011413.t002
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publication.
Results
Calibration results
Before evaluating the cost-effectiveness of the Mujer Segura
intervention, we assessed the ability of our model to predict
reasonable and valid estimates. Life expectancy obtained by the
model for Mexican women not in sex work was close to estimates
reported for Mexican women (77.96 years and 77.6 respectively)
[22]. HIV incidence for all women was estimated at 10.69 cases
per 100,000 person-years, varying between 5.43 and 13.32 per
100,000 for women over 55 years of age and younger women ages
18 to 54 respectively. Overall HIV incidence rates were close to
the CDC estimates for Latino women in the U.S. at 11.2 per
100,000 [28]. Similar to findings from other cohorts [29], median
survival post-HIV infection predicted by the model was 12 years
(interquartile range [IQR]: 9–14) when HAART was not
considered in the model, and varied according to the age when
HIV infection was acquired, showing increased survival for
women infected at younger ages. Considering HAART initiation
based on clinical CD4 count thresholds [19], the median survival
post-HIV infection was 24 years (IQR: 12–35).
Base case results
For a hypothetical cohort of 1,000 FSWs from Tijuana and
Ciudad Juarez, our analysis indicated that if the Mujer Segura
intervention were offered once-only, 33 HIV infections would be
prevented (95% CI: 30–37), increasing the QALE by 151 (95%
CI: 135–171) days per FSW, at a cost of US$183 (95% CI: $164–
$206) per QALY, and US$2,370 (95% CI: $2,092–$2,370) to
prevent each HIV case (Table 4). If the Mujer Segura intervention
were offered to FSWs annually, the model suggests an additional
29 (95% CI 26–33) HIV new cases prevented, increasing the
QALE by 132 additional days (95%CI: 109–149), at a cost per
additional QALY gained of US$1,075 (95%CI: US$931–$1,259),
and $13,413 (95%CI: $11,697–$15,077) per HIV case averted.
If we consider universal HAART access for clinically eligible
FSWs, the intervention offered annually is more effective and
becomes less costly compared with the other two scenarios (no
intervention or offering the intervention once-only). As seen in
Table 5, the intervention offered once increases the QALE by 11
days (95% CI: 8–14) for a net savings of US$2,485 (95% CI:
$2,100–$2,758). An additional 9 days (95% CI: 6–13) of QALE
are gained for the intervention offered annually, for an additional
net savings of US$1,592 (95% CI: $1,260–$1,929). Lifetime HIV
care costs averted for each HIV case prevented were estimated at
an average of US$60,000 (95% CI: $52,000–$73,000).
Sensitivity analyses
In two-way sensitivity analysis, we modeled the base case results
plus clinical benefits from universal HAART access for clinically-
indicated HIV infections (but ignoring the added costs of
HAART). We obtained a cost per QALY of $2,436 (95%CI:
$2,020–$3,359) for the intervention offered once (compared to no
intervention) and $14,136 (95% CI: $10,100–$20,360) for the
intervention offered annually (Table 6).
Table 3. Model base case costs and ranges used for sensitivity analyses.
Variable Base Case (range) Source
Personnel time costs
a Counseling sessions $5.00 (3.50–10.00)
b
Sample collection $5.00 (2.50–10.00) "
Laboratory tests Gonorrhea and Chlamydia $22.00 (15–30) "
Syphilis FTP rapid test $5.00 (2.50–7.50) "
Syphilis RPR
c $5.00 (2.50–7.50) "
HIV rapid test $3.50 (3.50–15.00) "
HIV confirmatory test
d $56.00 (40–65) "
Other Incentives
e $30.00 (15–45) "
STI treatment costs Azithromycin 1 gr. $14.00 (10–20) "
Ceftriaxone 125 mg. $7.70 (5–10) "
Benzathine penicillin G $5.00 (3–8) "
Three doses for HIV+ FSWs $15.00 (9–24) "
Annual fixed costs Space (rent) $3,600 (1200–7200) "
Telephone, internet $480 (350–600) "
Utilities $900 (600–1,200) "
Personnel training $500 (250–750) "
Mileage (outreach, recruiting) $9,600 (5–10K) "
Administrative personnel $9,000 (8–12K) "
Outreach workers $9,600 (8–10K) "
Start up costs $5,000 (2,500–7,500) "
aPersonnel wages per hour.
bData obtained from the Mujer Segura accounting records.
cRapid Plasma Reagin test for syphilis.
dHIV confirmed by immunofluorescence assay.
eEconomic incentive given to participants per visit.
doi:10.1371/journal.pone.0011413.t003
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in HIV incidence. Compared to no intervention, for the once-only
intervention, when HIV incidence increases to 4 per 100 person
years, the cost per QALY becomes more favorable at US$122;
when incidence falls to 0.3 per 100 person years, the cost per
QALY gained increases to US$1,202. For the intervention offered
annually, the cost per QALY ranged from US$600 to $7,409
compared to the once-only intervention, for an HIV incidence of 4
and 0.3 per 100 person years respectively (Figures 3 and 4).
The cost effectiveness acceptability curve (Figure 5) generated
from the probabilistic sensitivity analysis indicated that there was a
greater than 95% probability of a cost per QALY gained less than
US$25,499 for the interventon offered once and US$15,200 for
the intervention offered annually.
When the Mujer Segura intervention was targeted to the general
female population in Tijuana or Ciudad Juarez with HIV
incidence of 10 per 100,000 person-years and STI incidence of
10, 89 and 386 per 100,000 person-years for syphilis, gonorrhea
and Chlamydia respectively [21], the intervention is no longer
cost-effective, with a cost per QALY of US$98,000 (95%CI:
$43,000–$202,000), greater than three times the GDP in Mexico.
Discussion
Public health interventions that can effectively reduce HIV risk
behaviors among individuals at high risk, such as FSWs, are of
critical importance for successful HIV prevention programs [9],
especially in resource-limited countries such as Mexico, where
there is a dynamic, rapidly evolving HIV epidemic on the
country’s northern border with the U.S. [30]. Our study shows
that the Mujer Segura behavioral intervention targeted to FSWs
annually is highly cost-effective in Tijuana and Ciudad Juarez, and
is cost-saving when averted HAART costs due to the intervention
are considered. Furthermore, considering Mexico’s stage of the
epidemic, individually-based behavioral interventions targeted to
bridging populations like FSWs could have a high public health
impact at relatively low costs [12]. Even when we considered the
clinical health benefits from HAART and ignored the added costs,
the cost per QALY gained from this intervention remained below
three times the GDP per capita in Mexico and well below the
accepted cost-effectiveness threshold for Mexico according to
WHO guidelines [16].
The sensitivity analyses we conducted suggested that the cost-
effectiveness of expanding the Mujer Segura intervention to other
populations depends on factors driving HIV incidence. Specifi-
cally, our model suggests that it may not be cost-effective to target
the Mujer Segura intervention to the general female population (i.e.,
to women with low HIV and STI risk in Tijuana and Ciudad
Juarez). This finding is supported by health economists, who
suggest that the target population for an intervention should vary
according to the stage of the HIV epidemic [31]. For example, in
areas where overall HIV prevalence is either low or concentrated
in specific populations (such as in the Mexican context),
interventions should be prioritized for high-risk groups such as
FSWs and MSM. As HIV prevalence becomes generalized,
however, interventions should increasingly focus on the general
population [10]. Attention must also be given to differential
effectiveness of similar interventions among various subpopula-
tions. For example, our work suggests that FSWs who also inject
drugs may not benefit as much from our intervention [20], and
studies of cost-effectiveness are highly sensitive to contextual
variations in local epidemics. This emphasizes the need to select
interventions based on background characteristics of the specific
population as well as the stage of the epidemic [12].
Unlike other HIV-preventive interventions, the Mujer Segura
intervention showed efficacy beyond intermediate endpoints (e.g.,
reductions in reported unprotected sex acts) in reducing HIV
incidence among FSWs in community trials in two Mexican
border cities [26]. Our individually-administered intervention was
both efficacious and cost-effective in high-risk FSWs, but
alternative approaches may also be cost-effective in HIV
prevention among FSWs in different cultures and epidemic stages.
Sweat and colleagues [32] examined two FSW interventions in the
Dominican Republic, which is experiencing a more generalized
Table 5. Base case results considering universal access to highly active antiretroviral therapy (HAART) for a cohort of 1,000 female
sex workers (FSWs) in Tijuana.
Strategy Cost (US$) HIV cases prevented Incremental cost per HIV case averted QALY
a Incremental cost per QALY
a
MS
b annual 6,190,360 62 Cost-saving 23,580 Net savings
MS
b once 7,782,750 33 Dominated 23,553 Dominated
No intervention 10,268,730 — Dominated 23,523 Dominated
aCumulative quality-adjusted life years for a cohort of 1,000 FSWs.
bMujer Segura intervention.
doi:10.1371/journal.pone.0011413.t005
Table 4. Base case results not considering access to HAART for a cohort of 1,000 female sex workers (FSWs).
Strategy
Cost
(US$)
Incremental
cost (US$)
HIV cases
prevented
Incremental cost per
HIV case averted (US$) QALY
a
Incremental
QALY
a
Incremental cost
per QALY
a (US$)
No intervention 19,200 — 0 — 21,863 — —
MS
b once 97,400 78,200 33 2,370 22,290 427 183
MS
b annually 486,400 389,000 62 13,413 22,652 362 1,075
aCumulative quality-adjusted life years for a cohort of 1,000 FSWs.
bMujer Segura intervention.
doi:10.1371/journal.pone.0011413.t004
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factors (community mobilization, promotional media, and inter-
personal communication and counseling), and a second focused on
both environmental and structural factors (such as imposing
financial sanctions on sex establishment owners who failed to
follow the intervention). While both interventions resulted in cost-
effective outcomes, the intervention that included policy regulation
was substantially more cost-effective. Alternative prevention
approaches shown to be cost-effective in other populations include
structural interventions, female condom distribution, HIV rapid
tests, and voluntary HIV counseling and testing [33].
Underscoring the importance of evaluating the cost of
preventing new cases of HIV infection, the U.S. National Institutes
of Health funded the ‘‘Prevent AIDS: Network for Cost-
Effectiveness Analysis (PANCEA)’’ study. Information was col-
lected from 228 programs in five low- and middle-income
countries (including Mexico) in order to evaluate the relationship
between program efficiency (measured as the unit cost) and scale
of the program (measured in number of services delivered) [34].
The study found that prevention costs decrease with the scale of
the intervention [34]. These findings imply that HIV prevention
programs across the globe will become less costly as they continue
to grow, which argues in favor of implementation of highly cost-
effective behavioral intervention programs like Mujer Segura.
This cost-effectiveness analysis has a number of limitations.
First, data used to evaluate intervention efficacy were limited to six
months of follow-up, raising concerns about the durability of the
response beyond this period. Therefore, conservative estimates of
efficacy over 12 months were based on published reports from
trials among high-risk methamphetamine users in the U.S. using a
Table 6. Base case results considering universal access to HAART, ignoring added costs for antiretroviral medications, for a cohort
of 1,000 female sex workers (FSWs).
Strategy Cost (US$)
HIV cases
prevented
Incremental cost per HIV
case averted (US$) QALY
a
Incremental cost
per QALY
a (US$)
MS
b annual 19,500 — 23,497
MS
b once 97,500 33 2,370 23,529 2,435
No intervention 482,000 62 13,258 23,556 14,136
aCumulative quality-adjusted life years for a cohort of 1,000 FSWs.
bMujer Segura intervention.
doi:10.1371/journal.pone.0011413.t006
Figure 3. Tornado Diagram showing results of one way sensitivity analyses comparing no intervention to the Mujer Segura
intervention offered once only. The vertical dotted line represents the base-case analysis incremental cost per QALY (quality-adjusted life years)
gained. The numbers at the end of each bar represents the range over which each of the variables was changed. a=Changes in annual discount rate
used for costs and health benefits; b=Incidence is presented per 100 person-years; c=quality adjusted life years.
doi:10.1371/journal.pone.0011413.g003
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PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11413Figure 4. Tornado Diagram showing results of one way sensitivity analyses comparing the Mujer Segura intervention offered once
only and annually. The vertical dotted line represents the base-case analysis incremental cost per QALY (quality-adjusted life years) gained. The
numbers at the end of each bar represents the range over which each of the variables was changed. a=Changes in annual discount rate used for
costs and health benefits; b=Incidence is presented per 100 person-years; c=quality adjusted life years.
doi:10.1371/journal.pone.0011413.g004
Figure 5. Cost-effectiveness acceptability curve for the Mujer Segura intervention offered once or annually. Results of the probabilistic
sensitivity analysis, represented as a cost-effectiveness acceptability curve. The cost per QALY (quality adjusted life years) gained from the Mujer
Segura intervention is plotted on the x-axis, and the probability that the intervention is cost-effective across these values is plotted on the y-axis. The
Mujer Segura intervention offered once or annually resulted in a cost-effectiveness below a willingness to pay treshold of three times the GDP in
Mexico per QALY gained (equivalent to US$29,300). a=Mujer Segura behavioral intervention; b=Quality adjusted life year.
doi:10.1371/journal.pone.0011413.g005
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Tijuana and Ciudad Juarez participating in the Mujer Segura trial
represented a sample at high risk for HIV and STI infection; thus,
results from our analysis might not be generalizable to other
settings. Although multivariate sensitivity analyses were used to
present reliable confidence intervals, parameters used to model
HIV progression were obtained from published reports from other
populations in the US and Africa.
This brief behavioral intervention reduced incident STI and
HIV cases by 40%. Results from the present analyses suggest that
the intervention could have a significant public health impact
among FSWs in Tijuana and Ciudad Juarez, well below accepted
thresholds for cost-effectiveness in Mexico under all plausible
assumptions. Unfortunately, behavioral interventions continue to
be largely ignored in prevention strategies. While secondary
programs such as ‘‘seek and treat’’ have gained popularity and will
no doubt continue to play a major role in slowing the HIV
epidemic [35], our analysis demonstrates a way in which limited
public health resources can be optimized even after taking
HAART expenditures into account. Mexican health authorities
have expressed interest in scaling up the Mujer Segura intervention
throughout Mexico in collaboration with grass-roots, community-
based organizations. We therefore recommend that resources be
allocated to identifying both barriers and facilitators to large-scale
implementation of this and similar cost-effective behavioral
interventions.
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